Beijing Biostar Pharmaceuticals Co., Ltd. (HKG:2563)
Hong Kong
· Delayed Price · Currency is HKD 4.410
-0.930 (-17.42%)
Mar 31, 2025, 4:08 PM HKT
HKG:2563 Revenue
In the year 2023, Beijing Biostar Pharmaceuticals had annual revenue of 66.64M CNY with 103.03% growth.
Revenue
66.64M CNY
Revenue Growth
+103.03%
P/S Ratio
21.90
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.61B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 66.64M | 33.82M | 103.03% |
| Dec 31, 2022 | 32.82M | -38.24M | -53.82% |
| Dec 31, 2021 | 71.06M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.53B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| CSPC Pharmaceutical Group | 28.99B |
| Sino Biopharmaceutical | 30.72B |
| Akeso | 2.26B |